Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.To date, more than 600 patients and 170
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement")
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California-based late-stage clinical biopharmaceutical company, today announced the following
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) at 9:00
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung
